Selective Serotonin Reuptake Inhibitors in Pilot Fatalities of Civil Aviation Accidents, 1990-2001

Aviation Space and Environmental Medicine

Volumn 74, Issue 11, 2003, Pages 1169-1176

  Akin, Ahmet ^b   Chaturvedi, Arvind K ^a  

^a CIVIL AEROSPACE MEDICAL INSTITUTE   (United States)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Aviation forensic toxicology

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALCOHOL; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; NARCOTIC ANALGESIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AIRCRAFT ACCIDENT; AIRPLANE PILOT; ARTICLE; AVIATION; DRUG BLOOD LEVEL; DRUG STRUCTURE; FATALITY; HUMAN;

ACCIDENTS, AVIATION; AEROSPACE MEDICINE; CERTIFICATION; CITALOPRAM; DATABASES; ENVIRONMENTAL MONITORING; FLUOXETINE; HUMANS; PAROXETINE; POSTMORTEM CHANGES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SURVIVAL RATE; UNITED STATES;

EID: 0242334144     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Anastos N, McIntyre IM, Lynch MJ, Drummer OH. Postmortem concentrations of citalopram. J Forensic Sci 2002; 47:882-4.
2. Anderson WH, Prouty RW. Postmortem redistribution of drugs. In: Baselt RC, ed. Advances in analytical toxicology, Vol II. Chicago: Year Book Medical Publishers, Inc.; 1989:70-102.
3. Aviation Safety Research Act: Public Law 100-591 [H.R. 4686]. 100th U.S. Cong., 2nd Sess., 102 Stat. 3011 (Nov 3, 1988).
4. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001:447-83.
5. Baselt RC. Disposition of toxic drugs and chemicals in man. 6th ed. Foster City, CA: Biomedical Publications; 2002.
6. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31:444-69.
7. Beers MH, Berkow R, eds. The Merck manual of diagnosis and therapy. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:1525-44.
8. Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical handbook of psychotropic drugs. 11th rev. ed. Seattle, WA: Hogrefe & Huber Publishers; 2001:3-13.
9. Chaturvedi AK, Smith DR, Soper JW, et al. Characteristics and toxicological processing of postmortem pilot specimens from fatal civil aviation accidents. Aviat Space Environ Med 2003; 74:252-9.
10. Code of Federal Regulations (CFR). Title 14: Aeronautics and space, Chapter I, Part 67. Medical standards and certification, Subpart B: 107, Subpart C: 207, and Subpart D: 307. Washington, DC: U.S. Government Printing Office; 2002.
11. Code of Federal Regulations (CFR), Title 14: Aeronautics and space, Chapter I, Subchapters F and G. Washington, DC: U.S. Government Printing Office; 2002.
12. DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 1999; 19:443-66.
13. DeVane CL. SSRI safety considerations. Pharm Times 2002; 4:18-24.
14. Goeringer KE, Raymon L, Christian GD, Logan BK. Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J Forensic Sci 2000; 45:633-48.
15. Office of Aviation Medicine. Guide for aviation medical examiners. Washington, DC: U.S. Department of Transportation, Federal Aviation Administration; 1999:70.
16. Hudson DE. SSRI use in professional aircrew [abstract]. Aviat Space Environ Med 2002; 73:244-5.
17. Ireland RR. Pharmacologic considerations for serotonin reuptake inhibitor use by aviators. Aviat Space Environ Med 2002; 73: 421-9.
18. Jick SS, Dean AD, Jick H. Antidepressants and suicide. Br J Med 1995; 310(6974):215-8.
19. Jones DR. Aeromedical regulation of serotonin reuptake inhibitors in aviators [abstract]. Aviat Space Environ Med 2002; 73:245.
20. Lange M. Maintenance SRI use in professional pilots: the Canadian experience [abstract]. Aviat Space Environ Med 2002; 73:244.
21. Milner DA, Hall M, Davis GG, et al. Fatal multiple drug intoxication following acute sertraline use. J Anal Toxicol 1998; 21: 545-8.
22. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressant vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000; 101:17-25.
23. PDR Staff. Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Company, Inc.; 2002:3256-61.
24. Pounder DJ, Jones GR. Post-mortem drug redistribution: a toxicological nightmare. Forensic Sci Int 1990; 45:253-63.
25. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32(1, Suppl.):1-21.
26. Preskorn SH. Pharmacokinetics of antidepressant: why and how they are relevant to treatment. J Clin Psychiatry 1993; 54(9, Suppl.):14-34.
27. Prouty RW, Anderson WH. The forensic science implications of site and temporal influences on postmortem blood-drug concentrations. J Forensic Sci 1990; 35:243-70.
28. Silberman WS. The Federal Aviation Office of Aerospace Medicine's view on the use of SSRI's in airmen [abstract]. Aviat Space Environ Med 2002; 73:245.
29. SOFT/AAFS forensic toxicology laboratory guidelines. Colorado Spring, CO: Society of Forensic Toxicologists, Inc., and American Academy of Forensic Sciences; 1997.
30. Stahl SM. Psychopharmacology of antidepressant. London, UK: Martin Dunitz Ltd.; 1997; 39-59; 101-8.
31. Thibeault C. President's page. Aviat Space Environ Med 2002; 73:831.
32. Van Syoc D. Serotonin reuptake inhibitors in aircrew [abstract]. Aviat Space Environ Med 2002; 73:244.
33. Vermeulen T. Distribution of paroxetine in three postmortem cases. J Anal Toxicol 1998; 21:541-4.